Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1313182 | 0.84 | ALDH1A1 (0.34) | ALDH1A1CYP3A4DGAT1MMP1MMP9 | |
| SCHEMBL2475483 | 0.79 | DGAT1 (0.44) | ALDH1A1DGAT1L3MBTL1POLB | |
| SCHEMBL7435863 | 0.79 | MEN1 (0.36) | ALDH1A1DGAT1POLB | |
| SCHEMBL1316720 | 0.78 | ALDH1A1 (0.37) | ALDH1A1CYP3A4DGAT1MMP1MMP9 | |
| SCHEMBL3974919 | 0.76 | ALDH1A1 (0.38) | ALDH1A1CYP3A4DGAT1MMP1MMP9 | |
| SCHEMBL16705046 | 0.75 | DGAT1 (0.41) | ALDH1A1DGAT1L3MBTL1POLB | |
| SCHEMBL16153798 | 0.73 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL106266 | 0.73 | DGAT1 (0.39) | ALDH1A1DGAT1L3MBTL1POLB | |
| SCHEMBL12200986 | 0.73 | DGAT1 (0.39) | ALDH1A1DGAT1L3MBTL1HTTPOLB | |
| SCHEMBL22498238 | 0.72 | ALDH1A1 (0.36) | ALDH1A1CYP3A4DGAT1MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2331541-B1 | INDOLIZINE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2015-04-22 | — | — | EP | disclosed |
| EP-2331541-B1 | INDOLIZINE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2015-04-22 | — | — | EP | disclosed |
| US-8618300-B2 | Indolizine inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-31 | — | — | US | disclosed |
| US-20110275627-A1 | INDOLIZINE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| US-20110275627-A1 | INDOLIZINE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| US-20110275627-A1 | INDOLIZINE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| EP-2331541-A1 | INDOLIZINE INHIBITORS OF LEUKOTRIENE PRODUCTION | Boehringer Ingelheim International GmbH (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010027762-A1 | INDOLIZINE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010027762-A1 | INDOLIZINE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275627-A1 | INDOLIZINE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTB4R2, LTC4S | ALDH1A1 1602/4885CYP3A4 119/4885DGAT1 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.